Kymera Therapeutics, Inc.KYMRNASDAQ

Revenue (LTM)

$39M

-16.7% YoY

Net Income (LTM)

$-311M

-39.1% YoY

Free Cash Flow

$-234M

Revenue CAGR (5Y)

-14.3%

—Marginsstable

FCF($0.2B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	73	47↓35.7%	79↑67.8%	47↓40.1%	39↓16.7%
Gross Profit	73	47↓35.7%	79↑67.8%	47↓40.1%	39↓16.7%
Operating Income	-101	-161↓60.4%	-166↓2.7%	-262↓58.1%	-349↓33.5%
Net Income	-100	-155↓54.5%	-147↑5.1%	-224↓52.3%	-311↓39.1%
EBITDA	-98	-152↓55.3%	-143↑5.6%	-216↓51.0%	-303↓40.2%
EPS Diluted	-2.09	-2.87↓37.3%	-2.52↑12.2%	-2.98↓18.3%	-3.69↓23.8%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	48	68↑42.6%	110↑60.8%	120↑9.4%	357↑196.9%
Total Current Assets	451	419↓7.1%	405↓3.4%	510↑25.9%	871↑70.7%
Total Assets	606	603↓0.5%	576↓4.5%	978↑69.9%	1,743↑78.2%
Total Current Liabilities	93	71↓22.9%	86↑20.1%	68↓20.9%	83↑22.8%
Total Liabilities	146	113↓22.8%	181↑60.0%	142↓21.2%	163↑14.6%
Total Equity	460	490↑6.6%	395↓19.4%	836↑111.6%	1,580↑89.0%
Total Debt	18	17↓3.5%	85↑388.5%	88↑3.6%	82↓6.3%
Net Debt	-30	-51↓70.1%	-25↑50.5%	-32↓28.5%	-275↓745.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-129	-153↓18.7%	-103↑32.8%	-195↓89.2%	-233↓19.7%
Capital Expenditure	-2	-3↓77.6%	-34↓1115.8%	-13↑62.8%	-1↑88.7%
Free Cash Flow	-131	-156↓19.4%	-137↑11.9%	-207↓51.0%	-234↓13.0%
Stock-Based Comp	25	35↑42.1%	43↑21.5%	55↑27.6%	60↑8.9%
Net Change in Cash	21	20↓5.0%	41↑101.9%	10↓75.1%	237↑2204.7%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance